文献速递细菌感染、耐药与抗菌药物医院感染防控

纯化微生物组治疗对复发性艰难梭菌感染患者抗菌药物耐药基因丰度的影响

Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该研究为ECOSPOR III三期试验的事后分析,比较口服粪菌芽孢制剂VOS与安慰剂对复发性艰难梭菌感染患者抗菌药物耐药基因丰度的影响。结果显示第1周时VOS组耐药基因丰度下降幅度大于安慰剂组(P=0.003),与变形菌门减少和产芽孢厚壁菌门补充相关。作者认为微生物组重塑可能是减少胃肠道耐药基因定植的潜在新方法。

要点

  • 基线时两组耐药基因丰度相似,且均显著高于健康队列。
  • 第1周时VOS组耐药基因丰度下降幅度大于安慰剂组(P=0.003)。
  • 变形菌门和非产芽孢厚壁菌门丰度与耐药基因丰度相关,产芽孢厚壁菌门呈负相关。

核心结论

  • 这一概念验证分析提示,用厚壁菌门芽孢进行微生物组重塑可能是减少胃肠道抗菌药物耐药基因定植的潜在新方法。

研究设计与样本

  • ECOSPOR III三期试验的事后分析,成人复发性艰难梭菌感染患者随机接受VOS或安慰剂口服3天,在标准治疗抗生素之后给药。
  • 采用全宏基因组测序分析基线及治疗后第1、2、8、24周粪便的耐药基因和分类学特征。
  • 分析纳入了182例患者的基线(n=151)及治疗后连续粪便样本(共N=472),以及健康队列单时间点68份粪便样本。

主要发现

  • 182例患者中女性占59.9%,平均年龄65.5岁。
  • 基线时两组耐药基因丰度相似,且显著高于健康队列。
  • 第1周时VOS组耐药基因丰度下降幅度大于安慰剂组(P=0.003),同时变形菌门显著减少、产芽孢厚壁菌门补充,均与基线相比。
  • 变形菌门和非产芽孢厚壁菌门丰度与耐药基因丰度相关,而产芽孢厚壁菌门丰度呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The gastrointestinal microbiota is an important line of defense against colonization with antimicrobial resistant (AR) bacteria. In this post hoc analysis of the phase 3 ECOSPOR III trial, we assessed impact of a microbiota-based oral therapeutic (fecal microbiota spores, live; VOWST Oral Spores [VOS], formerly SER-109]; Seres Therapeutics) compared with placebo, on AR gene (ARG) abundance in patients with recurrent Clostridioides difficile infection (rCDI). METHODS: Adults with rCDI were randomized to receive VOS or placebo orally for 3 days following standard-of-care antibiotics. ARG and taxonomic profiles were generated using whole metagenomic sequencing of stool at baseline and weeks 1, 2, 8, and 24 posttreatment. RESULTS: Baseline (n = 151) and serial posttreatment stool samples collected through 24 weeks (total N = 472) from 182 patients (59.9% female; mean age: 65.5 years) in ECOSPOR III as well as 68 stool samples obtained at a single time point from a healthy cohort were analyzed. Baseline ARG abundance was similar between arms and significantly elevated versus the healthy cohort. By week 1, there was a greater decline in ARG abundance in VOS versus placebo (P = .003) in association with marked decline of Proteobacteria and repletion of spore-forming Firmicutes, as compared with baseline. We observed abundance of Proteobacteria and non-spore-forming Firmicutes were associated with ARG abundance, while spore-forming Firmicutes abundance was negatively associated. CONCLUSIONS: This proof-of-concept analysis suggests that microbiome remodeling with Firmicutes spores may be a potential novel approach to reduce ARG colonization in the gastrointestinal tract.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Straub TJ, Lombardo MJ, Bryant JA, et al. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2024. PMID: 37823484. doi:10.1093/cid/ciad636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。